Chronic graft-versus-host disease (cgvhd) diagnostic and risk biomarker panels, methods and uses thereof
OwnerKirk R. Schultz, Bernard Ng +1inventors
InventorsKirk R. Schultz, Bernard Ng, Geoff D. E. Cuvelier
Life of this patent
Estimating the term…
Abstract
This invention provides chronic graft-versus-host disease (cGVHD) biomarker panels for use in diagnostic and risk assignment methods. More particularly, the invention relates to particular combinations of biomarkers for diagnosing cGVHD and for predicting whether there is a low, intermediate or high risk of developing cGVHD. Furthermore, there are provided different treatment options depending on a patient's risk level or whether they have moderate to severe cGVHD.
Claims34
A chronic graft-versus-host disease (cGVHD) diagnostic biomarker panel, the panel comprising:
- (a) a NKREG Non-Cytolytic cell selected from one or more of:
- CD56Bright PerforinNegative CD56;
- and CD56Bright Granzyme BNegative CD56;
- (b) a Naïve Helper T cell selected from one or more of:
- CCR7+ CD45RA+ CD4+;
- PD1− CD45RA+ CD4+;
- CD27+ CD45RA+ CD4+;
- and CD31+ CD45RA+ CD4+;
- (c) a Naïve Cytotoxic T Cell that is CCR7+CD45RA+CD8+;
- (d) a Naïve Regulatory T Cell selected from one or more of:
- PD1− CD45RA+ Treg;
- and CD31+ CD45RA+ Treg;
- (e) a chemokine selected from one or more of:
- CXCL9;
- CXCL10;
- and CXCL11;
- (f) an intercellular adhesion molecule-1 (ICAM-1);
- (g) a T-cell immunoglobulin and mucin domain-3 (TIM-3);
- and
- (h) a suppression of tumorigenicity 2 (ST2).
A cGVHD risk assignment biomarker panel, the panel comprising:
- (a) a CD19+lymphocyte;
- (b) a transitional B cell selected from one or more of:
- a CD38− CD10− CD19+ B cell;
- a CD38dim CD10lo CD19+ B cell;
- and a CD38int CD10int CD19+B cell;
- (c) an NKREG Non-Cytolytic cell selected from one or more of:
- a CD56hi CD355hi CD56;
- a CD56hi PerforinNegative CD56;
- and a CD56hi Granzyme BNegative CD56;
- (d) a Cytolytic NK cell selected from one or more of:
- a CD56dim Phi CD56;
- a CD56dim CD69+CD56+;
- and a CD56lo Ghi CD56;
- (e) a CD3+ lymphocyte;
- (f a PD1++CD45RA+ CD4 Follicular T cell;
- (g) a PD1+ CD45RA+ CD8 T cell;
- (h) a CD31− CD45RA+ CD4 T cell;
- (i) an IgD+ CD27− CD19+ B cell;
- (j) a lysophosphatidylcholine (LYSOC) selected from one or more of:
- LYSOC14:0;
- LYSOC16:1;
- and LYSOC20:3;
- (k) a Taurine;
- (l) an Aspartic acid;
- (m) a Phenylalanine;
- (n) an alpha-Ketoglutaric acid;
- (o) a Fumaric acid;
- and
- (p) a phosphatidylcholine (PC) PC40:6AA.
Dependencies are inferred from the claim text.